Date Full Report Received


Date Abstract Report Received



Primary Investigator:

OIE-approved assays to identify the presence of African Swine Fever Virus (ASFV)-specific antibodies include an initial screening by ELISA-based tests followed by a confirmatory assay. False positive reactions in ELISA are not uncommon, especially when serum samples are in poor condition. The use of an ELISA test subsequently followed by confirmatory assays increases the specificity of the final results, and is recommended by the OIE. The Immunoblotting (IB) or Western blot (WB) test is the most widely used confirmatory method, allowing the visualization of antibody responses to ASFV proteins of various sizes. However the production, performance and interpretation of this test present certain limitations. It is a time consuming process, and needs to be performed in high containment BSL-3 facilities. In addition, there are significant difficulties in standardization and scalability of the WB assay, and it is often difficult to interpret the results of the assay due to a high background signal.

In this project, we utilized Multi Antigen Print Immunoassay (MAPIA) technology to develop a test for the detection of ASFV-specific antibodies as alternative to the current method based on WB analysis with cell-propagated ASFV antigens. The ASF MAPIA assay developed in this project uses recombinant ASFV proteins printed on nitrocellulose membranes for ASFV-specific antibody detection. Strips containing recombinant ASFV proteins can be produced in a BSL-2 laboratory and are easy to standardize and to scale up. Test evaluation data generated in this project demonstrated good specificity and ease of interpretation of the ASF MAPIA test results.